Connect with us

Media & Technology

Cyberlux Corporation (OTC: CYBL) Major Comeback Brewing as (DoD) Contractor Reports Strong Q2 Results & Upcoming Acquisitions

Published

2 years ago

on

Cyberlux Corporation (OTC: CYBL) is making a powerful comeback after a brief dip to lows near $0.01 after a steady uptrend which looks as if it will resume here as the Company announces important developments including Q2 financial results; Revenues for the three months ended June 30, 2021 were $367,231 as compared to $ -0- for the same period last year due to the impact of the COVID shutdown. The Company recorded an income from operations of $591,868 for the six months ended June 30, 2021. CYBL is now in the enviable position of gaining immediate business velocity by achieving OTC Pink Current status asap, continuing to build out its organization, focusing on its new business and new product pipeline, accelerating its South American projects and driving on its strategic IP development. The Company is focused on rapid growth through acquisition and stated several days ago they are ready to take advantage of the opportunities in front of them, including the upcoming 2-4 acquisitions in 2021, with the first one expected to conclude this month. A break over $0.019 and CYBL is back in a blue sky breakout. 

Microcapdaily first reported on CYBL on July 11 while the stock was still in the double zeroes stating at the time: It’s easy to get excited about CYBL; an active Department of Defense (DoD) contractor providing leading-edge, battle-tested lighting solutions to the U.S. Air Force, National Guard, Special Operations Command (SOCOM), and the U.S. Army. Management is hard at work getting their filings in order and moving to “pink current” Management has been working with the share structure and enacting a no reverse split policy as they move the AS from 20 billion down to 8.75 billion. Management states: We are expanding through acquisitions, across government agencies, and in targeted commercial and international markets with our renewable energy products, technologies and services, and having a healthy equity structure is vitally important. We are also making significant progress with our OTC Pink Current status and will have more information coming forward very soon.”  

Cyberlux Corporation (OTC: CYBL) operating out of Research Triangle Park, North Carolina is a leader in solid-state lighting innovation tht has developed breakthrough LED lighting and energy efficiency technology, with solutions available today in U.S. government agencies, commercial markets and international opportunities. The Company provides unique solutions to the Department of Defense (DoD), Commercial channels and Design Services customers. Since 2006, Cyberlux has provided leading-edge, battle-tested lighting solutions to the U.S. Air Force, National Guard, Special Operations Command (SOCOM), and the U.S. Army.  As the Company’s primary channel, Cyberlux supplies the DoD with light-weight, portable battery-powered advanced LED lighting systems for special operators, forward-base operations, security and maintenance lighting. After early consumer product trials, the Company has focused on DoD lighting technology and serving the Military, First Responder and related Commercial markets, primarily with the BrightEye Tactical Lighting System products. The Company’s mission is to be the trusted provider of advanced lighting solutions to Commercial, Government and Military organizations worldwide. The Company had a governent contract in Durham, North Carolina that ended on March 31, 2021. CYBL owns a suite of patented products that can be seen here. 

HomeThe BrightEye and WhiteEye, patented products, are advanced light-weight, portable, battery powered LED lighting systems for special operation actions, tactical deployments, remote operations and maintenance, emergency and disaster recovery programs. BrightEye and WhiteEye solutions are powered with milspec rechargeable power systems, with AC and solar powered options. BrightEye solutions deliver both White and Night Vision (NVG) Security Lighting. The NightEye Shelter Lighting System (NSLS) delivers energy efficient lighting available for semi-permanent shelters. The NSLS is designed to provide ideal light dispersion and illumination for shelter structures with White lighting and ‘Black-Out’ red lighting. In addition, the Laboratory Lighting System provides industry-leading lighting capability for laboratory and office environments. 

CYBL has been busy in July alone the Company accomplished a lot according to CEO Mark Schmidt who stated:  

– We reduce our Authorized Share level from the current 20 billion share level to 8.75 billion, a 56% reduction. This provides enough strategic equity to achieve our growth plans while protecting shareholders from any unnecessary dilution.  

– We instituted a “No Reverse Split Policy”, preventing CYBL from a reverse stock split for up to 5 years, and we confirmed our support of shareholders with measures like this No Reverse Split Policy whenever possible.  

– We reported that the Outstanding Share balance of 5.1B included 700M phantom restricted shares that were confirmed lost in 2018 and will never be tradeable, so the Effective Outstanding Share level improves the equity valuation for shareholders by 16%.  

– We set out our growth plans including expanding across government agencies, targeting specific commercial markets, driving growth in South America and expanding our technology IP, with the following priorities:  

  1. OTC Pink Current ASAP
  2. Build the Org-Key Hires 3Q
  3. Contracts-Pipeline 3Q/4Q
  4. Acquisition-Priorities 3Q
  5. Products 3Q/4Q
  6. S. America-Pipeline 3Q/4Q
    Strategic IP 4Q

To Find out the inside Scoop on CYBL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CYBL

– We confirmed that we have full OTCIQ access for the filings and the OTC approval process. We began uploading filings as committed and as they are approved. Per the OTCM requirements, the 2020 annual & the Q1 2021 reports are uploading next. We will be in good standing then and expect OTCM Pink Current soon after.  

– We provided a business update that the first acquisition transaction was moving forward as expected and we expect an August close and announcement.  

– We are also bullish on the next acquisition discussions we are having, and we will be updating the shareholders about this in a few weeks as we expect to move forward with this second acquisition.  

On July 18 CYBL released its second quarter of 2021 results which showed a significant increase in revenue year-to-year and demonstrated that the Company is accomplishing its growth milestones as it continues to recover from the impact of the COVID shutdown during 2020. The Company is now accelerating its growth through existing business channels, access to new markets, and through a Company-wide focus on acquisitions and joint ventures. CYBL has now posted all amended filings to OTC Markets and sees OTC Current status as imminent. 

Revenues for the three months ended June 30, 2021 were $367,231 as compared to $ -0- for the same period last year due to the impact of the COVID shutdown. The Company recorded an income from operations of $591,868 for the six months ended June 30, 2021. Operating expenses for the three months ended June 30, 2021 were ($153,681) as compared to $17,887 for the same period ended June 30, 2020. Included in the three months ended June 30, 2021 were the write-off of old liabilities in the amount of $231,625. 

Cyberlux Corporation CEO Mark Schmidt commented: During 2020, we took full advantage of the adversity presented by the unprecedented global shutdown and focused on the future of Cyberlux, where we were now and how we would grow. We re-envisioned what Cyberlux Corporation could be, what our company DNA could grow into, what competitive advantages we had inherent in our company after over a decade of Department of Defense (DoD) technology development and partnerships with the largest organizations in the world, including the U.S. Military, Boeing, and Cree. We also had significant sales and distribution experience with Walmart, Home Depot, Lowes and many, many others. Further, we now had a foundation in renewable energy and infrastructure projects, from the design and engineering required to build a solar power generation farm or a solar LED street light project, to the solar and lighting products required to execute. 

Going forward, we envision Cyberlux as a company that is “Harnessing the Future” and not just “Harnessing the Future of Light”, as we previously described the business. Now we will drive operational growth with current and future technologies, through fundamental organic growth and through an accelerated acquisitions and joint ventures strategy to align with companies pursuing technology and product extensions to ours, all with significant future growth. In the course of developing advanced technology products, we have come to identify core technology and product companies, and now these companies can become Cyberlux growth catalysts. Now we are harnessing the future, building Cyberlux into a leading technology company. 

The overall business environment so far in 2021 clearly shows we are in recovery from 2020, with Q2 revenues of $367,231 and income from operations of $591,868. We are also forecasting 2021 full year revenue as $5.1M across all business areas, with some upside opportunities in sight as well. As we push forward with our Operation Alpha growth plan, we have three priorities: (1) drive growth through aggressive business development, acquisitions and joint ventures; (2) address our core target markets with our DoD products, new specialty technology capabilities, solar and renewables, and with emerging infrastructure projects; and (3) gain immediate business velocity by achieving OTC Pink Current status asap, continuing to build out our organization, focusing on our new business and new product pipeline, accelerating our South American projects and driving on our strategic IP development. With the amended filings submitted today to the OTC Markets, we believe our Pink Current status will be granted next, which will serve as a catalyst for our next growth phase. We see a very exciting next six months for CYBL as we take advantage of the opportunities in front of us, including the upcoming 2-4 acquisitions in 2021, with the first one expected to conclude this month. 

For More on CYBL Subscribe Right Now!

CYBL is making a powerful comeback after a brief dip to lows near $0.01 after a steady uptrend which looks as if it will resume here as the Company announces important developments including Q2 financial results; Revenues for the three months ended June 30, 2021 were $367,231 as compared to $ -0- for the same period last year due to the impact of the COVID shutdown. The Company recorded an income from operations of $591,868 for the six months ended June 30, 2021. CYBL is now in the enviable position of gaining immediate business velocity by achieving OTC Pink Current status asap, continuing to build out its organization, focusing on its new business and new product pipeline, accelerating its South American projects and driving on its strategic IP development. The Company is focused on rapid growth through acquisition and stated several days ago they are ready to take advantage of the opportunities in front of them, including the upcoming 2-4 acquisitions in 2021, with the first one expected to conclude this month. A break over $0.019 and CYBL is back in a blue sky breakout. Microcapdaily first reported on CYBL on July 11 while the stock was still in the double zeroes stating at the time: It’s easy to get excited about CYBL; an active Department of Defense (DoD) contractor providing leading-edge, battle-tested lighting solutions to the U.S. Air Force, National Guard, Special Operations Command (SOCOM), and the U.S. Army. Management is hard at work getting their filings in order and moving to “pink current” Management has been working with the share structure and enacting a no reverse split policy as they move the AS from 20 billion down to 8.75 billion. Management states: We are expanding through acquisitions, across government agencies, and in targeted commercial and international markets with our renewable energy products, technologies and services, and having a healthy equity structure is vitally important. We are also making significant progress with our OTC Pink Current status and will have more information coming forward very soon.” We will be updating on CYBL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYBL.

Disclosure: we hold no position in CYBL either long or short and we have not been compensated for this article.

 

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

4 days ago

on

June 4, 2023

By

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by 3D Animation Production Company from Pixabay

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

1 week ago

on

May 29, 2023

By

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

3 weeks ago

on

May 19, 2023

By

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.